
CLAIMS

1. A compound of Formula (I),



(I)

wherein

ring **A** is monocyclic, bicyclic or spirocyclic cycloalkyl, cycloalkenyl or heterocyclyl, aryl or heteroaryl, and is optionally substituted with one to three R^1; wherein the heteroclyl contains one or more ring-forming heteroatoms independently selected from boron (B), Silicon (Si) oxygen (O), sulfur (S) or nitrogen (N), and the ring-forming sulfur is optionally substituted with two oxo (=O) groups;

ring **M** is monocyclic or fused bicyclic ring, containing 0-4 ring-forming heteroatoms independently selected from N, O or S; wherein a ring-forming carbon atom is optionally substituted with oxo (=O) to form a carbonyl group;

ring **B** is 5- or 6- membered aryl or heteroaryl, and is optionally substituted with one to three R^5;

X is $-CR^6R^7-O-$ or a bond;

n is 1 or 2;

Z is C or N;

each $\mathbf{R^1}$ independently is H, C_{1-7} alkyl, C_{2-7} alkenyl, C_{2-7} alkynyl, amino, alkylamino, dialkylamino, alkoxy, alkoxyalkyl, hydroxyalkyl, halogen, haloalkyl, -CN, cyanoalkyl, $-OR^{11}$, $-SO_2R^{11}$, $-SO_2NR^{12}R^{12'}$, $-NR^{12}SO_2R^{11}$, $-C(=O)-R^{11}$, $-COOR^{11}$, $-COONR^{12}R^{12'}$, $-C(=O)-NR^{12}R^{12'}$, $-P(=O)R^{12}R^{12'}$, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one to three R^{10};

each of $\mathbf{R^2}$ and $\mathbf{R^{2'}}$ is independently H, halogen, haloalkyl, alkoxy, alkoxyalkyl, hydroxyl, hydroxyalkyl, -CN, cyanoalkyl, C_{1-7} alkyl, cycloalkyl or heterocyclyl, wherein cycloalkyl or

heterocyclyl is optionally substituted with one or more R^{10};

each of **R^3** and **R^4** independently is H, alkyl, cycloalkyl or heterocyclyl, and is optionally substituted with one or more substituents independently selected from halogen, haloalkyl, -OH, hydroxyalkyl, alkoxy or -CN;

or, **R^3** and **R^4**, together with the atom to which they are both bonded, optionally form a 3-7 membered monocyclic, bicyclic or spirocyclic cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one to three R^{10};

each **R^5** independently is H, alkyl, halogen, haloalkyl, -OH, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, -CN, cyanoalkyl, amino, alkylamino, dialkylamino, aryl, heteroaryl, cycloalkyl, or heterocyclyl, wherein the aryl, heteroaryl, cycloalkyl or heterocyclyl is independently and optionally substituted with one or more R^{10};

each of **R^6** and **R^7** independently is H, alkyl, cycloalkyl or heterocyclyl, and is optionally substituted with one or more R^{10};

or, R^6 and R^7, together with the atom to which they are both bonded, optionally form a 3- to 7-membered monocyclic, bicyclic or spirocyclic cycloalkyl or heterocyclyl; wherein bicyclic or spirocyclic cycloalkyl or heterocyclyl is optionally substituted with one to three R^{10};

each **R^{10}** independently is H, alkyl, halogen, haloalkyl, -OH, hydroxyalkyl, -alkoxy, -alkoxyalkyl, CN or cyanoalkyl;

each of **R^{11}, R^{12}**, and **$R^{12'}$**, independently, is H, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, and is optionally substituted with one or more R^{10};

or, R^{12} and $R^{12'}$, together with the atom to which they are both bonded, optionally form a cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one to three R^{10};

the heterocyclyl in each occurrence with the provision not in ring A contains one to four ring-forming heteroatoms each of which is independently oxygen (O), sulfur (S) or nitrogen (N);

the heterocyclyl in each occurrence is a monocyclic, bicyclic, bridged bicyclic, fused bicyclic, spirocyclic or polycyclic ring; and is unsaturated or partially saturated;

the heteroaryl in each occurrence contains one to four ring-forming heteroatoms each of


which is independently oxygen (O), sulfur (S) or nitrogen (N);

any **H** is optionally replaced with deuterium (D);


p or **q** is independently 0, 1, 2, or 3;

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

2. The compound of claim 1, wherein the compound is Formula (II) or (III)



(II)



(III)









wherein

ring A is monocyclic, bicyclic or spirocyclic cycloalkyl, cycloalkenyl or heterocyclyl, aryl or heteroaryl, and is optionally substituted with one to three R^1; wherein the heteroclyl contains one or more ring-forming heteroatoms independently selected from boron (B), Silicon (Si) oxygen (O), sulfur (S) or nitrogen (N), and the ring-forming sulfur is optionally substituted with two oxo (=O) groups;


ring M is monocyclic or fused bicyclic ring, containing 0-4 ring-forming heteroatoms independently selected from N, O or S; wherein a ring-forming carbon atom is optionally substituted with oxo (=O) to form a carbonyl group;

ring B is 5 or 6 membered aryl or heteroaryl, and is optionally substituted with one to three R^5.


or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

3. The compound of claim 1 or 2, wherein  is , , , , , or ; or preferably, is .

4. The compound of any one of claims 1-3, wherein the compound is Formula (IV) or (V):















(IV)



(V)

5. The compound of claim 1, 2 or 4, wherein ring M is














; and ring M is optionally substituted with R^2 and $R^{2'}$;

Y_1 is NR, O or -CRR'-;

Y_2 is N, O or =CR-;

Y_3 is O, NR, or -CRR'-;

Y_4 is N, O or CR;

each of W_1 and W_2 is independently O, S, NR, or -CRR'-;











each of Z_1, Z_2, Z_3, Z_4, Z_5 and Z_6 is independently N or CR;


R or R' is H, alkyl, or cycloalkyl;


the dashed circle (◌) within a ring indicates the ring contains 1, 2, or 3 double bonds as long as the valence allows,

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

6. The compound of claim 5, wherein ring M is







; and ring M is optionally substituted with R^2 and $R^{2'}$.

7. The compound of claim 1, wherein halogen is -F or -Cl.


8. The compound of claim 1, 2 or 4, wherein ring A is


















; and ring A is optionally substituted with one to three R^1.

9. The compound of any one claims 1-8, wherein each R^1 is independently -OH, $C_{1\text{-}7}$ alkyl, -CN, $-SO_2R^{11}$, $-COOR^{11}$,$-C(=O)R^{11}$, $-NR^{12}SO_2R^{11}$, $-C(=O)-NR^{12}R^{12'}$, $-SO_2NR^{12}R^{12'}$, $-P(=O)R^{12}R^{12'}$, wherein each R^{11} is independently H, cycloalkyl, heterocyclyl, haloalkyl, alkyl, aryl, or heteroaryl, wherein the aryl, heteroaryl, cycloalkyl and heterocyclyl are optionally substituted with one more alkyl, halo, or haloalkyl; R^{12} and $R^{12'}$ are each independently is H, cycloalkyl, haloalkyl, or alkyl; or each of R^3 and R^4, independently, is H or alkyl, and any H is optionally replaced by D; or, R^3 and R^4, together with the atom to which they are both bonded, form a 3-7 membered cycloalkyl; or each of R^6 and R^7, independently, is H or alkyl.

















10. The compound of any one of claims 1-9, wherein the compound is selected from a group consisting of




,

,

,

,

,

,

,

,

,

,

,

,

,

,

















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,


,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





























,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,


,

,

,


























or

.

11. The compound of any one of claims 1-10, wherein the compound is a cytochrome P450 11A1 (CYP11A1) inhibitor.

12. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of any one of claims 1-11, and a pharmaceutically acceptable carrier or excipient.

13. Use of a compound of any one of claims 1-11 or a pharmaceutical composition of claim 12 for the manufacture of a medicament for the treatment of a disease or condition mediated by steroid hormone receptor.

14. The use of claim 13, wherein the steroid hormone receptor is androgen receptor (AR).

15. The use of claim 13, wherein the condition or disease mediated by steroid hormone receptor is cancer; or preferably, the cancer is prostate cancer or breast cancer; or preferably, the prostate cancer is castration-resistant prostate cancer (CRPC).